Label: LOVENOX- enoxaparin sodium injection 

  • Label RSS
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: New Drug Application

Drug Label Information

Updated 02/14

If you are a consumer or patient please visit this version.

  • BOXED WARNING(What is this?)

    WARNING: SPINAL/EPIDURAL HEMATOMAS

    Epidural or spinal hematomas may occur in patients who are anticoagulated with low molecular weight heparins (LMWH) or heparinoids and are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include:

    1
    Use of indwelling epidural catheters
    2
    Concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants.
    3
    A history of traumatic or repeated epidural or spinal punctures
    4
    A history of spinal deformity or spinal surgery

    Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary.

    Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated for thromboprophylaxis [see Warnings and Precautions (5.1) and Drug Interactions (7)].

    Close
  • HIGHLIGHTS OF PRESCRIBING INFORMATION
    These highlights do not include all the information needed to use Lovenox safely and effectively. See full prescribing information for Lovenox.
     
    Lovenox (enoxaparin sodium injection) for subcutaneous and intravenous use
    Initial U.S. Approval: 1993

    WARNING: SPINAL/EPIDURAL HEMATOMA

     

    Epidural or spinal hematomas may occur in patients who are anticoagulated with low molecular weight heparins (LMWH) or heparinoids and are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include:

    1
    Use of indwelling epidural catheters
    2
    Concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants
    3
    A history of traumatic or repeated epidural or spinal punctures
    4
    A history of spinal deformity or spinal surgery.

    Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary.

    Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated for thromboprophylaxis [see Warnings and Precautions (5.1) and Drug Interactions (7)].

    INDICATIONS AND USAGE

    Lovenox is a low molecular weight heparin [LMWH] indicated for:

    1
    Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery, knee replacement surgery, or medical patients with severely restricted mobility during acute illness ( 1.1)
    2
    Inpatient treatment of acute DVT with or without pulmonary embolism ( 1.2)
    3
    Outpatient treatment of acute DVT without pulmonary embolism. ( 1.2)
    4
    Prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction [MI] ( 1.3)
    5
    Treatment of acute ST-segment elevation myocardial infarction [STEMI] managed medically or with subsequent percutaneous coronary intervention [PCI] ( 1.4)

    DOSAGE AND ADMINISTRATION

    Indication Dose

    DVT prophylaxis in abdominal surgery

    40 mg SC once daily

    DVT prophylaxis in knee replacement surgery

    30 mg SC every 12 hours

    DVT prophylaxis in hip replacement surgery

    30 mg SC every 12 hours or 40 mg SC once daily

    DVT prophylaxis in medical patients

    40 mg SC once daily

    Inpatient treatment of acute DVT with or without pulmonary embolism

    1 mg/kg SC every 12 hours or 1.5 mg/kg SC once daily *

    Outpatient treatment of acute DVT without pulmonary embolism

    1 mg/kg SC every 12 hours *

    Unstable angina and non-Q-wave MI

    1 mg/kg SC every 12 hours (with aspirin)

    Acute STEMI in patients <75 years of age
    [For dosing in subsequent PCI, see Dosage and Administration (2.1)]

    30 mg single IV bolus plus a 1 mg/kg SC dose followed by 1 mg/kg SC every 12 hours (with aspirin)

    Acute STEMI in patients ≥75 years of age

    0.75 mg/kg SC every 12 hours (no bolus) (with aspirin)

    1
    See recommended durations for Lovenox therapy ( 2.1)
    2
    *See recommendations regarding transitioning to warfarin therapy ( 2.1)
    3
    Adjust the dose for patients with severe renal impairment ( 2.2, 8.7)

    DOSAGE FORMS AND STRENGTHS

    100 mg/mL concentration (3.1):

    1
    Prefilled syringes: 30 mg/0.3 mL, 40 mg/0.4 mL
    2
    Graduated prefilled syringes: 60 mg/0.6 mL, 80 mg/0.8 mL,100 mg/1 mL
    3
    Multiple-dose vial: 300 mg/3 mL

    150 mg/mL concentration (3.2):

    1
    Graduated prefilled syringes: 120 mg/0.8 mL, 150 mg/1 mL

    CONTRAINDICATIONS

    1
    Active major bleeding ( 4)
    2
    Thrombocytopenia with a positive in vitro test for anti-platelet antibody in the presence of enoxaparin sodium ( 4)
    3
    Hypersensitivity to enoxaparin sodium ( 4)
    4
    Hypersensitivity to heparin or pork products ( 4)
    5
    Hypersensitivity to benzyl alcohol [for multi-dose formulation only] ( 4)

    WARNINGS AND PRECAUTIONS

    1
    Increased risk of hemorrhage: Use with caution in patients at risk ( 5.1)
    2
    Percutaneous coronary revascularization: Obtain hemostasis at the puncture site before sheath removal ( 5.2)
    3
    Concomitant medical conditions: Use with caution in patients with bleeding diathesis, uncontrolled arterial hypertension or history of recent gastrointestinal ulceration, diabetic retinopathy, renal dysfunction, or hemorrhage ( 5.3)
    4
    History of heparin-induced thrombocytopenia: Use with caution ( 5.4)
    5
    Thrombocytopenia: Monitor thrombocytopenia closely ( 5.5)
    6
    Interchangeability with other heparins: Do not exchange with heparin or other LMWHs ( 5.6)
    7
    Pregnant women with mechanical prosthetic heart valves and their fetuses, may be at increased risk and may need more frequent monitoring and dosage adjustment ( 5.7)

    ADVERSE REACTIONS

    Most common adverse reactions (>1%) were bleeding, anemia, thrombocytopenia, elevation of serum aminotransferase, diarrhea, and nausea (6.1)

     

    To report SUSPECTED ADVERSE REACTIONS, contact sanofi-aventis at 1-800-633-1610 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

    DRUG INTERACTIONS

    Discontinue agents which may enhance hemorrhage risk prior to initiation of Lovenox or conduct close clinical and laboratory monitoring (5.9, 7)

    USE IN SPECIFIC POPULATIONS

    1
    Severe Renal Impairment: Adjust dose for patients with creatinine clearance <30mL/min ( 2.2, 8.7)
    2
    Geriatric Patients: Monitor for increased risk of bleeding ( 8.5)
    3
    Patients with mechanical heart valves: Not adequately studied ( 8.6)
    4
    Hepatic Impairment: Use with caution. ( 8.8)
    5
    Low-Weight Patients: Observe for signs of bleeding ( 8.9)

    See 17 for PATIENT COUNSELING INFORMATION.

    Revised: 2/2014

    Close
  • FULL PRESCRIBING INFORMATION: CONTENTS*

    WARNING: SPINAL/EPIDURAL HEMATOMAS

    1 INDICATIONS AND USAGE

    1.1 Prophylaxis of Deep Vein Thrombosis

    1.2 Treatment of Acute Deep Vein Thrombosis

    1.3 Prophylaxis of Ischemic Complications of Unstable Angina and Non-Q-Wave Myocardial Infarction

    1.4 Treatment of Acute ST-Segment Elevation Myocardial Infarction

    2 DOSAGE AND ADMINISTRATION

    2.1 Adult Dosage

    2.2 Renal Impairment

    2.3 Geriatric Patients with Acute ST-Segment Elevation Myocardial Infarction

    2.4 Administration

    3 DOSAGE FORMS AND STRENGTHS

    3.1 100 mg/mL Concentration

    3.2 150 mg/mL Concentration

    4 CONTRAINDICATIONS

    5 WARNINGS AND PRECAUTIONS

    5.1 Increased Risk of Hemorrhage

    5.2 Percutaneous Coronary Revascularization Procedures

    5.3 Use of Lovenox with Concomitant Medical Conditions

    5.4 History of Heparin-Induced Thrombocytopenia

    5.5 Thrombocytopenia

    5.6 Interchangeability with Other Heparins

    5.7 Pregnant Women with Mechanical Prosthetic Heart Valves

    5.8 Benzyl Alcohol

    5.9 Laboratory Tests

    6 ADVERSE REACTIONS

    6.1 Clinical Trials Experience

    6.2 Postmarketing Experience

    7 DRUG INTERACTIONS

    8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    8.3 Nursing Mothers

    8.4 Pediatric Use

    8.5 Geriatric Use

    8.6 Patients with Mechanical Prosthetic Heart Valves

    8.7 Renal Impairment

    8.8 Hepatic Impairment

    8.9 Low-Weight Patients

    10 OVERDOSAGE

    11 DESCRIPTION

    12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    12.2 Pharmacodynamics

    12.3 Pharmacokinetics

    13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

    13.2 Animal Toxicology and/or Pharmacology

    13.3 Reproductive and Developmental Toxicology

    14 CLINICAL STUDIES

    14.1 Prophylaxis of Deep Vein Thrombosis Following Abdominal Surgery in Patients at Risk for Thromboembolic Complications

    14.2 Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery

    14.3 Prophylaxis of Deep Vein Thrombosis in Medical Patients with Severely Restricted Mobility During Acute Illness

    14.4 Treatment of Deep Vein Thrombosis with or without Pulmonary Embolism

    14.5 Prophylaxis of Ischemic Complications in Unstable Angina and Non-Q-Wave Myocardial Infarction

    14.6 Treatment of Acute ST-Segment Elevation Myocardial Infarction

    16 HOW SUPPLIED/STORAGE AND HANDLING

    17 PATIENT COUNSELING INFORMATION

    *
    Sections or subsections omitted from the full prescribing information are not listed.
    Close
  • 1 INDICATIONS AND USAGE

    1.1 Prophylaxis of Deep Vein Thrombosis

    Lovenox® is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE):

    1
    in patients undergoing abdominal surgery who are at risk for thromboembolic complications [see Clinical Studies (14.1)].
    2
    in patients undergoing hip replacement surgery, during and following hospitalization.
    3
    in patients undergoing knee replacement surgery.
    4
    in medical patients who are at risk for thromboembolic complications due to severely restricted mobility during acute illness.

    1.2 Treatment of Acute Deep Vein Thrombosis

    Lovenox is indicated for:

    1
    the inpatient treatment of acute deep vein thrombosis with or without pulmonary embolism, when administered in conjunction with warfarin sodium.
    2
    the outpatient treatment of acute deep vein thrombosis without pulmonary embolism when administered in conjunction with warfarin sodium.

    1.3 Prophylaxis of Ischemic Complications of Unstable Angina and Non-Q-Wave Myocardial Infarction

    Lovenox is indicated for the prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction, when concurrently administered with aspirin.

    1.4 Treatment of Acute ST-Segment Elevation Myocardial Infarction

    Lovenox, when administered concurrently with aspirin, has been shown to reduce the rate of the combined endpoint of recurrent myocardial infarction or death in patients with acute ST-segment elevation myocardial infarction (STEMI) receiving thrombolysis and being managed medically or with percutaneous coronary intervention (PCI).

    Close
  • 2 DOSAGE AND ADMINISTRATION

    All patients should be evaluated for a bleeding disorder before administration of Lovenox, unless the medication is needed urgently. Since coagulation parameters are unsuitable for monitoring Lovenox activity, routine monitoring of coagulation parameters is not required [see Warnings and Precautions (5.9)].

    For subcutaneous use, Lovenox should not be mixed with other injections or infusions. For intravenous use (i.e., for treatment of acute STEMI), Lovenox can be mixed with normal saline solution (0.9%) or 5% dextrose in water.

    Lovenox is not intended for intramuscular administration.

    2.1 Adult Dosage

    Abdominal Surgery: In patients undergoing abdominal surgery who are at risk for thromboembolic complications, the recommended dose of Lovenox is 40 mg once a day administered by SC injection with the initial dose given 2 hours prior to surgery. The usual duration of administration is 7 to 10 days; up to 12 days administration has been administered in clinical trials.

    Hip or Knee Replacement Surgery: In patients undergoing hip or knee replacement surgery, the recommended dose of Lovenox is 30 mg every 12 hours administered by SC injection. Provided that hemostasis has been established, the initial dose should be given 12 to 24 hours after surgery. For hip replacement surgery, a dose of 40 mg once a day SC, given initially 12 (±3) hours prior to surgery, may be considered. Following the initial phase of thromboprophylaxis in hip replacement surgery patients, it is recommended that continued prophylaxis with Lovenox 40 mg once a day be administered by SC injection for 3 weeks. The usual duration of administration is 7 to 10 days; up to 14 days administration has been administered in clinical trials.

    Medical Patients During Acute Illness: In medical patients at risk for thromboembolic complications due to severely restricted mobility during acute illness, the recommended dose of Lovenox is 40 mg once a day administered by SC injection. The usual duration of administration is 6 to 11 days; up to 14 days of Lovenox has been administered in the controlled clinical trial.

    Treatment of Deep Vein Thrombosis with or without Pulmonary Embolism: In outpatient treatment, patients with acute deep vein thrombosis without pulmonary embolism who can be treated at home, the recommended dose of Lovenox is 1 mg/kg every 12 hours administered SC. In inpatient (hospital) treatment, patients with acute deep vein thrombosis with pulmonary embolism or patients with acute deep vein thrombosis without pulmonary embolism (who are not candidates for outpatient treatment), the recommended dose of Lovenox is 1 mg/kg every 12 hours administered SC or 1.5 mg/kg once a day administered SC at the same time every day. In both outpatient and inpatient (hospital) treatments, warfarin sodium therapy should be initiated when appropriate (usually within 72 hours of Lovenox). Lovenox should be continued for a minimum of 5 days and until a therapeutic oral anticoagulant effect has been achieved (International Normalization Ratio 2.0 to 3.0). The average duration of administration is 7 days; up to 17 days of Lovenox administration has been administered in controlled clinical trials.

    Unstable Angina and Non-Q-Wave Myocardial Infarction: In patients with unstable angina or non-Q-wave myocardial infarction, the recommended dose of Lovenox is 1 mg/kg administered SC every 12 hours in conjunction with oral aspirin therapy (100 to 325 mg once daily). Treatment with Lovenox should be prescribed for a minimum of 2 days and continued until clinical stabilization. The usual duration of treatment is 2 to 8 days; up to 12.5 days of Lovenox has been administered in clinical trials [see Warnings and Precautions (5.2) and Clinical Studies (14.5)].

    Treatment of Acute ST-Segment Elevation Myocardial Infarction: In patients with acute ST-segment elevation myocardial infarction, the recommended dose of Lovenox is a single IV bolus of 30 mg plus a 1 mg/kg SC dose followed by 1 mg/kg administered SC every 12 hours (maximum 100 mg for the first two doses only, followed by 1 mg/kg dosing for the remaining doses). Dosage adjustments are recommended in patients ≥75 years of age [see Dosage and Administration (2.3)]. All patients should receive aspirin as soon as they are identified as having STEMI and maintained with 75 to 325 mg once daily unless contraindicated.

    When administered in conjunction with a thrombolytic (fibrin-specific or non-fibrin specific), Lovenox should be given between 15 minutes before and 30 minutes after the start of fibrinolytic therapy. In the pivotal clinical study, the Lovenox treatment duration was 8 days or until hospital discharge, whichever came first. An optimal duration of treatment is not known, but it is likely to be longer than 8 days.

    For patients managed with percutaneous coronary intervention (PCI): If the last Lovenox SC administration was given less than 8 hours before balloon inflation, no additional dosing is needed. If the last Lovenox SC administration was given more than 8 hours before balloon inflation, an IV bolus of 0.3 mg/kg of Lovenox should be administered [see Warnings and Precautions (5.2)].

    2.2 Renal Impairment

    Although no dose adjustment is recommended in patients with moderate (creatinine clearance 30–50 mL/min) and mild (creatinine clearance 50–80 mL/min) renal impairment, all such patients should be observed carefully for signs and symptoms of bleeding.

    The recommended prophylaxis and treatment dosage regimens for patients with severe renal impairment (creatinine clearance <30 mL/min) are described in Table 1 [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)].

    Table 1
    Dosage Regimens for Patients with Severe Renal Impairment
    (creatinine clearance <30mL/minute)
    Indication Dosage Regimen

    Prophylaxis in abdominal surgery

    30 mg administered SC once daily

    Prophylaxis in hip or knee replacement surgery

    30 mg administered SC once daily

    Prophylaxis in medical patients during acute illness

    30 mg administered SC once daily

    Inpatient treatment of acute deep vein thrombosis with or without pulmonary embolism, when administered in conjunction with warfarin sodium

    1 mg/kg administered SC once daily

    Outpatient treatment of acute deep vein thrombosis without pulmonary embolism, when administered in conjunction with warfarin sodium

    1 mg/kg administered SC once daily

    Prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction, when concurrently administered with aspirin

    1 mg/kg administered SC once daily

    Treatment of acute ST-segment elevation myocardial infarction in patients <75 years of age, when administered in conjunction with aspirin

    30 mg single IV bolus plus a 1 mg/kg SC dose followed by 1 mg/kg administered SC once daily.

    Treatment of acute ST-segment elevation myocardial infarction in geriatric patients ≥75 years of age, when administered in conjunction with aspirin

    1 mg/kg administered SC once daily (no initial bolus)

    2.3 Geriatric Patients with Acute ST-Segment Elevation Myocardial Infarction

    For treatment of acute ST-segment elevation myocardial infarction in geriatric patients ≥75 years of age, do not use an initial IV bolus. Initiate dosing with 0.75 mg/kg SC every 12 hours (maximum 75 mg for the first two doses only, followed by 0.75 mg/kg dosing for the remaining doses) [see Use in Specific Populations (8.5) and Clinical Pharmacology (12.3)].

    No dose adjustment is necessary for other indications in geriatric patients unless kidney function is impaired [see Dosage and Administration (2.2)].

    2.4 Administration

    Lovenox is a clear, colorless to pale yellow sterile solution, and as with other parenteral drug products, should be inspected visually for particulate matter and discoloration prior to administration.

    The use of a tuberculin syringe or equivalent is recommended when using Lovenox multiple-dose vials to assure withdrawal of the appropriate volume of drug.

    Lovenox must not be administered by intramuscular injection. Lovenox is intended for use under the guidance of a physician.

    For subcutaneous administration, patients may self-inject only if their physicians determine that it is appropriate and with medical follow-up, as necessary. Proper training in subcutaneous injection technique (with or without the assistance of an injection device) should be provided.

    Subcutaneous Injection Technique: Patients should be lying down and Lovenox administered by deep SC injection. To avoid the loss of drug when using the 30 and 40 mg prefilled syringes, do not expel the air bubble from the syringe before the injection. Administration should be alternated between the left and right anterolateral and left and right posterolateral abdominal wall. The whole length of the needle should be introduced into a skin fold held between the thumb and forefinger; the skin fold should be held throughout the injection. To minimize bruising, do not rub the injection site after completion of the injection.

    Lovenox prefilled syringes and graduated prefilled syringes are for single, one-time use only and are available with a system that shields the needle after injection.

    Remove the prefilled syringe from the blister packaging by peeling at the arrow as directed on the blister. Do not remove by pulling on the plunger as this may damage the syringe.

    1.
    Remove the needle shield by pulling it straight off the syringe (see Figure A). If adjusting the dose is required, the dose adjustment must be done prior to injecting the prescribed dose to the patient.
    Figure A
     
    Figure A
    2.
    Inject using standard technique, pushing the plunger to the bottom of the syringe (see Figure B).
    Figure B
     
    Figure B
    3.
    Remove the syringe from the injection site keeping your finger on the plunger rod (see Figure C).
    Figure C
     
    Figure C
    4.
    Orient the needle away from you and others, and activate the safety system by firmly pushing the plunger rod. The protective sleeve will automatically cover the needle and an audible "click" will be heard to confirm shield activation (see Figure D).
    Figure D
     
    Figure D
    5.
    Immediately dispose of the syringe in the nearest sharps container (see Figure E).
    Figure E
     
    Figure E

    NOTE:

    1
    The safety system can only be activated once the syringe has been emptied.
    2
    Activation of the safety system must be done only after removing the needle from the patient's skin.
    3
    Do not replace the needle shield after injection.
    4
    The safety system should not be sterilized.

    Activation of the safety system may cause minimal splatter of fluid. For optimal safety activate the system while orienting it downwards away from yourself and others.

    Intravenous (Bolus) Injection Technique: For intravenous injection, the multiple-dose vial should be used. Lovenox should be administered through an intravenous line. Lovenox should not be mixed or co-administered with other medications. To avoid the possible mixture of Lovenox with other drugs, the intravenous access chosen should be flushed with a sufficient amount of saline or dextrose solution prior to and following the intravenous bolus administration of Lovenox to clear the port of drug. Lovenox may be safely administered with normal saline solution (0.9%) or 5% dextrose in water.

    Close
  • 3 DOSAGE FORMS AND STRENGTHS

    Lovenox is available in two concentrations:

    3.1 100 mg/mL Concentration

    -Prefilled Syringes

    30 mg/0.3 mL, 40 mg/0.4 mL

    -Graduated Prefilled Syringes

    60 mg/0.6 mL, 80 mg/0.8 mL, 100 mg/1 mL

    -Multiple-Dose Vials

    300 mg/3 mL

    3.2 150 mg/mL Concentration

    -Graduated Prefilled Syringes

    120 mg/0.8 mL, 150 mg/1 mL

    Close
  • 4 CONTRAINDICATIONS

    1
    Active major bleeding
    2
    Thrombocytopenia associated with a positive in vitro test for anti-platelet antibody in the presence of enoxaparin sodium
    3
    Known hypersensitivity to enoxaparin sodium ( e.g., pruritus, urticaria, anaphylactic/anaphylactoid reactions) [see Adverse Reactions (6.2)]
    4
    Known hypersensitivity to heparin or pork products
    5
    Known hypersensitivity to benzyl alcohol (which is in only the multi-dose formulation of Lovenox) [see Warnings and Precautions (5.8)]
    Close
  • 5 WARNINGS AND PRECAUTIONS

    5.1 Increased Risk of Hemorrhage

    Cases of epidural or spinal hematomas have been reported with the associated use of Lovenox and spinal/epidural anesthesia or spinal puncture resulting in long-term or permanent paralysis. The risk of these events is higher with the use of post-operative indwelling epidural catheters, with the concomitant use of additional drugs affecting hemostasis such as NSAIDs, with traumatic or repeated epidural or spinal puncture, or in patients with a history of spinal surgery or spinal deformity [see Boxed Warning,Adverse Reactions (6.2) and Drug Interactions (7)].

    Lovenox should be used with extreme caution in conditions with increased risk of hemorrhage, such as bacterial endocarditis, congenital or acquired bleeding disorders, active ulcerative and angiodysplastic gastrointestinal disease, hemorrhagic stroke, or shortly after brain, spinal, or ophthalmological surgery, or in patients treated concomitantly with platelet inhibitors.

    Major hemorrhages including retroperitoneal and intracranial bleeding have been reported. Some of these cases have been fatal.

    Bleeding can occur at any site during therapy with Lovenox. An unexplained fall in hematocrit or blood pressure should lead to a search for a bleeding site.

    5.2 Percutaneous Coronary Revascularization Procedures

    To minimize the risk of bleeding following the vascular instrumentation during the treatment of unstable angina, non-Q-wave myocardial infarction and acute ST-segment elevation myocardial infarction, adhere precisely to the intervals recommended between Lovenox doses. It is important to achieve hemostasis at the puncture site after PCI. In case a closure device is used, the sheath can be removed immediately. If a manual compression method is used, sheath should be removed 6 hours after the last IV/SC Lovenox. If the treatment with enoxaparin sodium is to be continued, the next scheduled dose should be given no sooner than 6 to 8 hours after sheath removal. The site of the procedure should be observed for signs of bleeding or hematoma formation [see Dosage and Administration (2.1)].

    5.3 Use of Lovenox with Concomitant Medical Conditions

    Lovenox should be used with care in patients with a bleeding diathesis, uncontrolled arterial hypertension or a history of recent gastrointestinal ulceration, diabetic retinopathy, renal dysfunction and hemorrhage.

    5.4 History of Heparin-Induced Thrombocytopenia

    Lovenox should be used with extreme caution in patients with a history of heparin-induced thrombocytopenia.

    5.5 Thrombocytopenia

    Thrombocytopenia can occur with the administration of Lovenox.

    Moderate thrombocytopenia (platelet counts between 100,000/mm3 and 50,000/mm3) occurred at a rate of 1.3% in patients given Lovenox, 1.2% in patients given heparin, and 0.7% in patients given placebo in clinical trials.

    Platelet counts less than 50,000/mm3 occurred at a rate of 0.1% in patients given Lovenox, in 0.2% of patients given heparin, and 0.4% of patients given placebo in the same trials.

    Thrombocytopenia of any degree should be monitored closely. If the platelet count falls below 100,000/mm3, Lovenox should be discontinued. Cases of heparin-induced thrombocytopenia with thrombosis have also been observed in clinical practice. Some of these cases were complicated by organ infarction, limb ischemia, or death [see Warnings and Precautions (5.4)].

    5.6 Interchangeability with Other Heparins

    Lovenox cannot be used interchangeably (unit for unit) with heparin or other low molecular weight heparins as they differ in manufacturing process, molecular weight distribution, anti-Xa and anti-IIa activities, units, and dosage. Each of these medicines has its own instructions for use.

    5.7 Pregnant Women with Mechanical Prosthetic Heart Valves

    The use of Lovenox for thromboprophylaxis in pregnant women with mechanical prosthetic heart valves has not been adequately studied. In a clinical study of pregnant women with mechanical prosthetic heart valves given enoxaparin (1 mg/kg twice daily) to reduce the risk of thromboembolism, 2 of 8 women developed clots resulting in blockage of the valve and leading to maternal and fetal death. Although a causal relationship has not been established these deaths may have been due to therapeutic failure or inadequate anticoagulation. No patients in the heparin/warfarin group (0 of 4 women) died. There also have been isolated postmarketing reports of valve thrombosis in pregnant women with mechanical prosthetic heart valves while receiving enoxaparin for thromboprophylaxis. Women with mechanical prosthetic heart valves may be at higher risk for thromboembolism during pregnancy, and, when pregnant, have a higher rate of fetal loss from stillbirth, spontaneous abortion and premature delivery. Therefore, frequent monitoring of peak and trough anti-Factor Xa levels, and adjusting of dosage may be needed [see Use in Specific Populations (8.6)].

    5.8 Benzyl Alcohol

    Lovenox multiple-dose vials contain benzyl alcohol as a preservative. The administration of medications containing benzyl alcohol as a preservative to premature neonates has been associated with a fatal "gasping syndrome". Because benzyl alcohol may cross the placenta, Lovenox multiple-dose vials, preserved with benzyl alcohol, should be used with caution in pregnant women and only if clearly needed [see Use in Specific Populations (8.1)].

    5.9 Laboratory Tests

    Periodic complete blood counts, including platelet count, and stool occult blood tests are recommended during the course of treatment with Lovenox. When administered at recommended prophylaxis doses, routine coagulation tests such as Prothrombin Time (PT) and Activated Partial Thromboplastin Time (aPTT) are relatively insensitive measures of Lovenox activity and, therefore, unsuitable for monitoring. Anti-Factor Xa may be used to monitor the anticoagulant effect of Lovenox in patients with significant renal impairment. If during Lovenox therapy abnormal coagulation parameters or bleeding should occur, anti-Factor Xa levels may be used to monitor the anticoagulant effects of Lovenox [see Clinical Pharmacology (12.3)].

    Close
  • 6 ADVERSE REACTIONS

    6.1 Clinical Trials Experience

    The following serious adverse reactions are also discussed in other sections of the labeling:

    1
    Spinal/epidural hematoma [see Boxed Warning and Warnings and Precautions (5.1)]
    2
    Increased Risk of Hemorrhage [see Warnings and Precautions (5.1)]
    3
    Thrombocytopenia [see Warnings and Precautions (5.5)]

    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

    During clinical development for the approved indications, 15,918 patients were exposed to enoxaparin sodium. These included 1,228 for prophylaxis of deep vein thrombosis following abdominal surgery in patients at risk for thromboembolic complications, 1,368 for prophylaxis of deep vein thrombosis following hip or knee replacement surgery, 711 for prophylaxis of deep vein thrombosis in medical patients with severely restricted mobility during acute illness, 1,578 for prophylaxis of ischemic complications in unstable angina and non-Q-wave myocardial infarction, 10,176 for treatment of acute ST-elevation myocardial infarction, and 857 for treatment of deep vein thrombosis with or without pulmonary embolism. Enoxaparin sodium doses in the clinical trials for prophylaxis of deep vein thrombosis following abdominal or hip or knee replacement surgery or in medical patients with severely restricted mobility during acute illness ranged from 40 mg SC once daily to 30 mg SC twice daily. In the clinical studies for prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction doses were 1 mg/kg every 12 hours and in the clinical studies for treatment of acute ST-segment elevation myocardial infarction enoxaparin sodium doses were a 30 mg IV bolus followed by 1 mg/kg every 12 hours SC.

    Hemorrhage

    The incidence of major hemorrhagic complications during Lovenox treatment has been low.

    The following rates of major bleeding events have been reported during clinical trials with Lovenox [see Tables 2 to 7].

    Table 2 Major Bleeding Episodes Following Abdominal and Colorectal Surgerya
    Dosing Regimen
    Indications Lovenox
    40 mg q.d. SC
    Heparin
    5000 U q8h SC

    Abdominal Surgery

    n = 555
    23 (4%)

    n = 560
    16 (3%)

    Colorectal Surgery

    n = 673
    28 (4%)

    n = 674
    21 (3%)

    a) Bleeding complications were considered major: (1) if the hemorrhage caused a significant clinical event, or (2) if accompanied by a hemoglobin decrease ≥ 2 g/dL or transfusion of 2 or more units of blood products. Retroperitoneal, intraocular, and intracranial hemorrhages were always considered major.

    Table 3 Major Bleeding Episodes Following Hip or Knee Replacement Surgerya
    Indications Dosing Regimen
    Lovenox
    40 mg q.d. SC
    Lovenox
    30 mg q12h SC
    Heparin
    15,000 U/24h SC

    Hip Replacement Surgery without Extended Prophylaxisb

    n = 786
    31 (4%)

    n = 541
    32 (6%)

    Hip Replacement Surgery with Extended Prophylaxis

    Peri-operative Periodc

    n = 288
    4 (2%)

    Extended Prophylaxis Periodd

    n = 221
    0 (0%)

    Knee Replacement Surgery without Extended Prophylaxisb

    n = 294
    3 (1%)

    n = 225
    3 (1%)

    a) Bleeding complications were considered major: (1) if the hemorrhage caused a significant clinical event, or (2) if accompanied by a hemoglobin decrease ≥ 2 g/dL or transfusion of 2 or more units of blood products. Retroperitoneal and intracranial hemorrhages were always considered major. In the knee replacement surgery trials, intraocular hemorrhages were also considered major hemorrhages.

    b) Lovenox 30 mg every 12 hours SC initiated 12 to 24 hours after surgery and continued for up to 14 days after surgery

    c) Lovenox 40 mg SC once a day initiated up to 12 hours prior to surgery and continued for up to 7 days after surgery

    d) Lovenox 40 mg SC once a day for up to 21 days after discharge

    NOTE: At no time point were the 40 mg once a day pre-operative and the 30 mg every 12 hours post-operative hip replacement surgery prophylactic regimens compared in clinical trials.

    Injection site hematomas during the extended prophylaxis period after hip replacement surgery occurred in 9% of the Lovenox patients versus 1.8% of the placebo patients.

    Table 4 Major Bleeding Episodes in Medical Patients with Severely Restricted Mobility During Acute Illnessa
    Indications Dosing Regimen
    Lovenoxb
    20 mg q.d. SC
    Lovenoxb
    40 mg q.d. SC
    Placebob

    Medical Patients During Acute Illness

    n = 351
    1 (<1%)

    n = 360
    3 (<1%)

    n = 362
    2 (<1%)

    a) Bleeding complications were considered major: (1) if the hemorrhage caused a significant clinical event, (2) if the hemorrhage caused a decrease in hemoglobin of ≥ 2 g/dL or transfusion of 2 or more units of blood products. Retroperitoneal and intracranial hemorrhages were always considered major although none were reported during the trial.

    b) The rates represent major bleeding on study medication up to 24 hours after last dose.

    Table 5 Major Bleeding Episodes in Deep Vein Thrombosis with or without Pulmonary Embolism Treatment a
    Dosing Regimenb
    Indication Lovenox
    1.5 mg/kg q.d. SC
    Lovenox
    1 mg/kg q12h SC
    Heparin
    aPTT Adjusted IV Therapy

    Treatment of DVT and PE

    n = 298
    5 (2%)

    n = 559
    9 (2%)

    n = 554
    9 (2%)

    a) Bleeding complications were considered major: (1) if the hemorrhage caused a significant clinical event, or (2) if accompanied by a hemoglobin decrease ≥ 2 g/dL or transfusion of 2 or more units of blood products. Retroperitoneal, intraocular, and intracranial hemorrhages were always considered major.

    b) All patients also received warfarin sodium (dose-adjusted according to PT to achieve an INR of 2.0 to 3.0) commencing within 72 hours of Lovenox or standard heparin therapy and continuing for up to 90 days.

    Table 6 Major Bleeding Episodes in Unstable Angina and Non-Q-Wave Myocardial Infarction
    Indication Dosing Regimen
    Lovenoxa
    1 mg/kg q12h SC
    Heparina
    aPTT Adjusted IV Therapy

    Unstable Angina and Non-Q-Wave MIb,c

    n = 1578
    17 (1%)

    n = 1529
    18 (1%)

    a) The rates represent major bleeding on study medication up to 12 hours after dose.

    b) Aspirin therapy was administered concurrently (100 to 325 mg per day).

    c) Bleeding complications were considered major: (1) if the hemorrhage caused a significant clinical event, or (2) if accompanied by a hemoglobin decrease by ≥ 3 g/dL or transfusion of 2 or more units of blood products. Intraocular, retroperitoneal, and intracranial hemorrhages were always considered major.

    Table 7 Major Bleeding Episodes in Acute ST-Segment Elevation Myocardial Infarction
    Dosing Regimen
    Indication Lovenoxa *
    Initial 30 mg IV bolus followed by 1 mg/kg q12h SC
    Heparina *
    aPTT Adjusted IV Therapy
    *
    The rates represent major bleeding (including ICH) up to 30 days
    Bleedings were considered major if the hemorrhage caused a significant clinical event associated with a hemoglobin decrease by ≥ 5 g/dL. ICH were always considered major.

    Acute ST-Segment Elevation Myocardial Infarction

    n = 10176
    n (%)

    n = 10151
    n (%)

    - Major bleeding (including ICH)b

    211 (2.1)

    138 (1.4)

    - Intracranial hemorrhages (ICH)

    84 (0.8)

    66 (0.7)

    Elevations of Serum Aminotransferases

    Asymptomatic increases in aspartate (AST [SGOT]) and alanine (ALT [SGPT]) aminotransferase levels greater than three times the upper limit of normal of the laboratory reference range have been reported in up to 6.1% and 5.9% of patients, respectively, during treatment with Lovenox. Similar significant increases in aminotransferase levels have also been observed in patients and healthy volunteers treated with heparin and other low molecular weight heparins. Such elevations are fully reversible and are rarely associated with increases in bilirubin.

    Since aminotransferase determinations are important in the differential diagnosis of myocardial infarction, liver disease, and pulmonary emboli, elevations that might be caused by drugs like Lovenox should be interpreted with caution.

    Local Reactions

    Mild local irritation, pain, hematoma, ecchymosis, and erythema may follow SC injection of Lovenox.

    Adverse Reactions in Patients Receiving Lovenox for Prophylaxis or Treatment of DVT, PE:

    Other adverse reactions that were thought to be possibly or probably related to treatment with Lovenox, heparin, or placebo in clinical trials with patients undergoing hip or knee replacement surgery, abdominal or colorectal surgery, or treatment for DVT and that occurred at a rate of at least 2% in the Lovenox group, are provided below [see Tables 8 to 11].

    Table 8 Adverse Reactions Occurring at ≥2% Incidence in Lovenox-Treated Patients Undergoing Abdominal or Colorectal Surgery
    Adverse Reaction Dosing Regimen
    Lovenox
    40 mg q.d. SC
    n = 1228
    %
    Heparin
    5000 U q8h SC
    n = 1234
    %
    Severe Total Severe Total

    Hemorrhage

    <1

    7

    <1

    6

    Anemia

    <1

    3

    <1

    3

    Ecchymosis

    0

    3

    0

    3

    Table 9 Adverse Reactions Occurring at ≥2% Incidence in Lovenox-Treated Patients Undergoing Hip or Knee Replacement Surgery
    Adverse Reaction Dosing Regimen
    Lovenox
    40 mg q.d. SC
    Lovenox
    30 mg q12h SC
    Heparin
    15,000 U/24h SC
    Placebo
    q12h SC
    Peri-operative Period
    n = 288a
    %
    Extended Prophylaxis Period
    n = 131b
    %
    n = 1080
    %
    n = 766
    %
    n = 115
    %
    Severe Total Severe Total Severe Total Severe Total Severe Total

    Fever

    0

    8

    0

    0

    <1

    5

    <1

    4

    0

    3

    Hemorrhage

    <1

    13

    0

    5

    <1

    4

    1

    4

    0

    3

    Nausea

    <1

    3

    <1

    2

    0

    2

    Anemia

    0

    16

    0

    <2

    <1

    2

    2

    5

    <1

    7

    Edema

    <1

    2

    <1

    2

    0

    2

    Peripheral edema

    0

    6

    0

    0

    <1

    3

    <1

    4

    0

    3

    a) Data represent Lovenox 40 mg SC once a day initiated up to 12 hours prior to surgery in 288 hip replacement surgery patients who received Lovenox peri-operatively in an unblinded fashion in one clinical trial.

    b) Data represent Lovenox 40 mg SC once a day given in a blinded fashion as extended prophylaxis at the end of the peri-operative period in 131 of the original 288 hip replacement surgery patients for up to 21 days in one clinical trial.

    Table 10 Adverse Reactions Occurring at ≥2% Incidence in Lovenox-Treated Medical Patients with Severely Restricted Mobility During Acute Illness
    Adverse Reaction Dosing Regimen
    Lovenox
    40 mg q.d. SC
    n = 360
    %
    Placebo
    q.d. SC
    n = 362
    %

    Dyspnea

    3.3

    5.2

    Thrombocytopenia

    2.8

    2.8

    Confusion

    2.2

    1.1

    Diarrhea

    2.2

    1.7

    Nausea

    2.5

    1.7

    Table 11 Adverse Reactions Occurring at ≥2% Incidence in Lovenox-Treated Patients Undergoing Treatment of Deep Vein Thrombosis with or without Pulmonary Embolism
    Adverse Reaction Dosing Regimen
    Lovenox
    1.5 mg/kg q.d. SC

    n = 298
    %
    Lovenox
    1 mg/kg q12h SC

    n = 559
    %
    Heparin
    aPTT Adjusted IV Therapy
    n = 544
    %
    Severe Total Severe Total Severe Total

    Injection Site Hemorrhage

    0

    5

    0

    3

    <1

    <1

    Injection Site Pain

    0

    2

    0

    2

    0

    0

    Hematuria

    0

    2

    0

    <1

    <1

    2

    Adverse Events in Lovenox-Treated Patients with Unstable Angina or Non-Q-Wave Myocardial Infarction:

    Non-hemorrhagic clinical events reported to be related to Lovenox therapy occurred at an incidence of ≤1%.

    Non-major hemorrhagic events, primarily injection site ecchymoses and hematomas, were more frequently reported in patients treated with SC Lovenox than in patients treated with IV heparin.

    Serious adverse events with Lovenox or heparin in a clinical trial in patients with unstable angina or non-Q-wave myocardial infarction that occurred at a rate of at least 0.5% in the Lovenox group are provided below [see Table 12].

    Table 12 Serious Adverse Events Occurring at ≥0.5% Incidence in Lovenox-Treated Patients with Unstable Angina or Non-Q-Wave Myocardial Infarction
    Adverse Event Dosing Regimen
    Lovenox
    1 mg/kg q12h SC
    n = 1578
    n (%)
    Heparin
    aPTT Adjusted IV Therapy
    n = 1529
    n (%)

    Atrial fibrillation

    11 (0.70)

    3 (0.20)

    Heart failure

    15 (0.95)

    11 (0.72)

    Lung edema

    11 (0.70)

    11 (0.72)

    Pneumonia

    13 (0.82)

    9 (0.59)

    Adverse Reactions in Lovenox-Treated Patients with Acute ST-Segment Elevation Myocardial Infarction:

    In a clinical trial in patients with acute ST-segment elevation myocardial infarction, the only adverse reaction that occurred at a rate of at least 0.5% in the Lovenox group was thrombocytopenia (1.5%).

    6.2 Postmarketing Experience

    The following adverse reactions have been identified during postapproval use of Lovenox. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

    There have been reports of epidural or spinal hematoma formation with concurrent use of Lovenox and spinal/epidural anesthesia or spinal puncture. The majority of patients had a post-operative indwelling epidural catheter placed for analgesia or received additional drugs affecting hemostasis such as NSAIDs. Many of the epidural or spinal hematomas caused neurologic injury, including long-term or permanent paralysis.

    Local reactions at the injection site (e.g. nodules, inflammation, oozing), systemic allergic reactions (e.g. pruritus, urticaria, anaphylactic/anaphylactoid reactions including shock), vesiculobullous rash, rare cases of hypersensitivity cutaneous vasculitis, purpura, skin necrosis (occurring at either the injection site or distant from the injection site), thrombocytosis, and thrombocytopenia with thrombosis [see Warnings and Precautions (5.5)] have been reported.

    Cases of hyperkalemia have been reported. Most of these reports occurred in patients who also had conditions that tend toward the development of hyperkalemia (e.g., renal dysfunction, concomitant potassium-sparing drugs, administration of potassium, hematoma in body tissues). Very rare cases of hyperlipidemia have also been reported, with one case of hyperlipidemia, with marked hypertriglyceridemia, reported in a diabetic pregnant woman; causality has not been determined.

    Cases of headache, hemorrhagic anemia, eosinophilia, alopecia, hepatocellular and cholestatic liver injury have been reported.

    Osteoporosis has also been reported following long-term therapy.

    Close
  • 7 DRUG INTERACTIONS

    Whenever possible, agents which may enhance the risk of hemorrhage should be discontinued prior to initiation of Lovenox therapy. These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, salicylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone. If co-administration is essential, conduct close clinical and laboratory monitoring [see Warnings and Precautions (5.9)].

    Close
  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Pregnancy Category B

    All pregnancies have a background risk of birth defect, loss, or other adverse outcome regardless of drug exposure. The fetal risk summary below describes the potential of Lovenox to increase the risk of developmental abnormalities above the background risk.

    Fetal Risk Summary

    Lovenox does not cross the placenta, and is not expected to result in fetal exposure to the drug. Human data from a retrospective cohort study, which included 693 live births, suggest that Lovenox does not increase the risk of major developmental abnormalities. Based on animal data, enoxaparin is not predicted to increase the risk of major developmental abnormalities (see Data).

    Clinical Considerations

    Pregnancy alone confers an increased risk for thromboembolism that is even higher for women with thromboembolic disease and certain high risk pregnancy conditions. While not adequately studied, pregnant women with mechanical prosthetic heart valves may be at even higher risk for thrombosis [see Warnings and Precautions (5.7) and Use in Specific Populations (8.6)]. Pregnant women with thromboembolic disease, including those with mechanical prosthetic heart valves and those with inherited or acquired thrombophilias, have an increased risk of other maternal complications and fetal loss regardless of the type of anticoagulant used.

    All patients receiving anticoagulants, including pregnant women, are at risk for bleeding. Pregnant women receiving enoxaparin should be carefully monitored for evidence of bleeding or excessive anticoagulation. Consideration for use of a shorter acting anticoagulant should be specifically addressed as delivery approaches [see Boxed Warning]. Hemorrhage can occur at any site and may lead to death of mother and/or fetus. Pregnant women should be apprised of the potential hazard to the fetus and the mother if enoxaparin is administered during pregnancy.

    It is not known if monitoring of anti-Factor Xa activity and dose adjustment (by weight or anti-Factor Xa activity) of Lovenox affect the safety and the efficacy of the drug during pregnancy.

    Cases of "gasping syndrome" have occurred in premature infants when large amounts of benzyl alcohol have been administered (99–405 mg/kg/day). The multiple-dose vial of Lovenox contains 15 mg benzyl alcohol per 1 mL as a preservative [see Warnings and Precautions (5.8)].

    Data

    1
    Human Data - There are no adequate and well-controlled studies in pregnant women.
     
    A retrospective study reviewed the records of 604 women who used enoxaparin during pregnancy. A total of 624 pregnancies resulted in 693 live births. There were 72 hemorrhagic events (11 serious) in 63 women. There were 14 cases of neonatal hemorrhage. Major congenital anomalies in live births occurred at rates (2.5%) similar to background rates.
     
    There have been postmarketing reports of fetal death when pregnant women received Lovenox. Causality for these cases has not been determined. Insufficient data, the underlying disease, and the possibility of inadequate anticoagulation complicate the evaluation of these cases.
     
    A clinical study using enoxaparin in pregnant women with mechanical prosthetic heart valves has been conducted [see Warnings and Precautions (5.7)].
    2
    Animal Data - Teratology studies have been conducted in pregnant rats and rabbits at SC doses of enoxaparin up to 15 times the recommended human dose (by comparison with 2 mg/kg as the maximum recommended daily dose). There was no evidence of teratogenic effects or fetotoxicity due to enoxaparin. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

    8.3 Nursing Mothers

    It is not known whether Lovenox is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Lovenox, a decision should be made whether to discontinue nursing or discontinue Lovenox, taking into account the importance of Lovenox to the mother and the known benefits of nursing.

    8.4 Pediatric Use

    Safety and effectiveness of Lovenox in pediatric patients have not been established.

    8.5 Geriatric Use

    Prevention of Deep Vein Thrombosis in Hip, Knee and Abdominal Surgery; Treatment of Deep Vein Thrombosis, Prevention of Ischemic Complications of Unstable Angina and Non-Q-wave Myocardial Infarction

    Over 2800 patients, 65 years and older, have received Lovenox in pivotal clinical trials. The efficacy of Lovenox in the geriatric (≥65 years) was similar to that seen in younger patients (<65 years). The incidence of bleeding complications was similar between geriatric and younger patients when 30 mg every 12 hours or 40 mg once a day doses of Lovenox were employed. The incidence of bleeding complications was higher in geriatric patients as compared to younger patients when Lovenox was administered at doses of 1.5 mg/kg once a day or 1 mg/kg every 12 hours. The risk of Lovenox-associated bleeding increased with age. Serious adverse events increased with age for patients receiving Lovenox. Other clinical experience (including postmarketing surveillance and literature reports) has not revealed additional differences in the safety of Lovenox between geriatric and younger patients. Careful attention to dosing intervals and concomitant medications (especially antiplatelet medications) is advised. Lovenox should be used with care in geriatric patients who may show delayed elimination of enoxaparin. Monitoring of geriatric patients with low body weight (<45 kg) and those predisposed to decreased renal function should be considered [see Warnings and Precautions (5.9) and Clinical Pharmacology (12.3)].

    Treatment of Acute ST-Segment Elevation Myocardial Infarction

    In the clinical study for treatment of acute ST-segment elevation myocardial infarction, there was no evidence of difference in efficacy between patients ≥75 years of age (n = 1241) and patients less than 75 years of age (n=9015). Patients ≥75 years of age did not receive a 30 mg IV bolus prior to the normal dosage regimen and had their SC dose adjusted to 0.75 mg/kg every 12 hours [see Dosage and Administration (2.3)]. The incidence of bleeding complications was higher in patients ≥65 years of age as compared to younger patients (<65 years).

    8.6 Patients with Mechanical Prosthetic Heart Valves

    The use of Lovenox has not been adequately studied for thromboprophylaxis in patients with mechanical prosthetic heart valves and has not been adequately studied for long-term use in this patient population. Isolated cases of prosthetic heart valve thrombosis have been reported in patients with mechanical prosthetic heart valves who have received enoxaparin for thromboprophylaxis. Some of these cases were pregnant women in whom thrombosis led to maternal and fetal deaths. Insufficient data, the underlying disease and the possibility of inadequate anticoagulation complicate the evaluation of these cases. Pregnant women with mechanical prosthetic heart valves may be at higher risk for thromboembolism [see Warnings and Precautions (5.7)].

    8.7 Renal Impairment

    In patients with renal impairment, there is an increase in exposure of enoxaparin sodium. All such patients should be observed carefully for signs and symptoms of bleeding. Because exposure of enoxaparin sodium is significantly increased in patients with severe renal impairment (creatinine clearance <30 mL/min), a dosage adjustment is recommended for therapeutic and prophylactic dosage ranges. No dosage adjustment is recommended in patients with moderate (creatinine clearance 30–50 mL/min) and mild (creatinine clearance 50–80 mL/min) renal impairment [see Dosage and Administration (2.2) and Clinical Pharmacology (12.3)]. In patients with renal failure, treatment with enoxaparin has been associated with the development of hyperkalemia [see Adverse Reactions (6.2)].

    8.8 Hepatic Impairment

    The impact of hepatic impairment on enoxaparin's exposure and antithrombotic effect has not been investigated. Caution should be exercised when administering enoxaparin to patients with hepatic impairment.

    8.9 Low-Weight Patients

    An increase in exposure of enoxaparin sodium with prophylactic dosages (non-weight adjusted) has been observed in low-weight women (<45 kg) and low-weight men (<57 kg). All such patients should be observed carefully for signs and symptoms of bleeding [see Clinical Pharmacology (12.3)].

    Close
  • 10 OVERDOSAGE

    Accidental overdosage following administration of Lovenox may lead to hemorrhagic complications. Injected Lovenox may be largely neutralized by the slow IV injection of protamine sulfate (1% solution). The dose of protamine sulfate should be equal to the dose of Lovenox injected: 1 mg protamine sulfate should be administered to neutralize 1 mg Lovenox, if enoxaparin sodium was administered in the previous 8 hours. An infusion of 0.5 mg protamine per 1 mg of enoxaparin sodium may be administered if enoxaparin sodium was administered greater than 8 hours previous to the protamine administration, or if it has been determined that a second dose of protamine is required. The second infusion of 0.5 mg protamine sulfate per 1 mg of Lovenox may be administered if the aPTT measured 2 to 4 hours after the first infusion remains prolonged.

    If at least 12 hours have elapsed since the last enoxaparin sodium injection, protamine administration may not be required; however, even with higher doses of protamine, the aPTT may remain more prolonged than following administration of heparin. In all cases, the anti-Factor Xa activity is never completely neutralized (maximum about 60%). Particular care should be taken to avoid overdosage with protamine sulfate. Administration of protamine sulfate can cause severe hypotensive and anaphylactoid reactions. Because fatal reactions, often resembling anaphylaxis, have been reported with protamine sulfate, it should be given only when resuscitation techniques and treatment of anaphylactic shock are readily available. For additional information consult the labeling of protamine sulfate injection products.

    Close
  • 11 DESCRIPTION

    Lovenox is a sterile aqueous solution containing enoxaparin sodium, a low molecular weight heparin. The pH of the injection is 5.5 to 7.5.

    Enoxaparin sodium is obtained by alkaline depolymerization of heparin benzyl ester derived from porcine intestinal mucosa. Its structure is characterized by a 2-O-sulfo-4-enepyranosuronic acid group at the non-reducing end and a 2-N,6-O-disulfo-D-glucosamine at the reducing end of the chain. About 20% (ranging between 15% and 25%) of the enoxaparin structure contains an 1,6 anhydro derivative on the reducing end of the polysaccharide chain. The drug substance is the sodium salt. The average molecular weight is about 4500 daltons. The molecular weight distribution is:

                 <2000 daltons             ≤20%

                 2000 to 8000 daltons  ≥68%

                 >8000 daltons             ≤18%
     

    STRUCTURAL FORMULA

    Chemical Structure

    R

    Xa= 15 to 25%

    Chemical Structure

    n= 0 to 20

    100 - X

    H

    n =1 to 21

    a) X = Percent of polysaccharide chain containing 1,6 anhydro derivative on the reducing end.

    Lovenox 100 mg/mL Concentration contains 10 mg enoxaparin sodium (approximate anti-Factor Xa activity of 1000 IU [with reference to the W.H.O. First International Low Molecular Weight Heparin Reference Standard]) per 0.1 mL Water for Injection.

    Lovenox 150 mg/mL Concentration contains 15 mg enoxaparin sodium (approximate anti-Factor Xa activity of 1500 IU [with reference to the W.H.O. First International Low Molecular Weight Heparin Reference Standard]) per 0.1 mL Water for Injection.

    The Lovenox prefilled syringes and graduated prefilled syringes are preservative-free and intended for use only as a single-dose injection. The multiple-dose vial contains 15 mg benzyl alcohol per 1 mL as a preservative [see Dosage and Administration (2) and How Supplied (16)].

    Close
  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    Enoxaparin is a low molecular weight heparin which has antithrombotic properties.

    12.2 Pharmacodynamics

    In humans, enoxaparin given at a dose of 1.5 mg/kg subcutaneously (SC) is characterized by a higher ratio of anti-Factor Xa to anti-Factor IIa activity (mean ± SD, 14.0 ± 3.1) (based on areas under anti-Factor activity versus time curves) compared to the ratios observed for heparin (mean±SD, 1.22 ± 0.13). Increases of up to 1.8 times the control values were seen in the thrombin time (TT) and the activated partial thromboplastin time (aPTT). Enoxaparin at a 1 mg/kg dose (100 mg/mL concentration), administered SC every 12 hours to patients in a large clinical trial resulted in aPTT values of 45 seconds or less in the majority of patients (n = 1607). A 30 mg IV bolus immediately followed by a 1 mg/kg SC administration resulted in aPTT post-injection values of 50 seconds. The average aPTT prolongation value on Day 1 was about 16% higher than on Day 4.

    12.3 Pharmacokinetics

    Absorption: Pharmacokinetic trials were conducted using the 100 mg/mL formulation. Maximum anti-Factor Xa and anti-thrombin (anti-Factor IIa) activities occur 3 to 5 hours after SC injection of enoxaparin. Mean peak anti-Factor Xa activity was 0.16 IU/mL (1.58 mcg/mL) and 0.38 IU/mL (3.83 mcg/mL) after the 20 mg and the 40 mg clinically tested SC doses, respectively. Mean (n = 46) peak anti-Factor Xa activity was 1.1 IU/mL at steady state in patients with unstable angina receiving 1 mg/kg SC every 12 hours for 14 days. Mean absolute bioavailability of enoxaparin, after 1.5 mg/kg given SC, based on anti-Factor Xa activity is approximately 100% in healthy subjects.

    A 30 mg IV bolus immediately followed by a 1 mg/kg SC every 12 hours provided initial peak anti-Factor Xa levels of 1.16 IU/mL (n=16) and average exposure corresponding to 84% of steady-state levels. Steady state is achieved on the second day of treatment.

    Enoxaparin pharmacokinetics appear to be linear over the recommended dosage ranges [see Dosage and Administration (2)]. After repeated subcutaneous administration of 40 mg once daily and 1.5 mg/kg once-daily regimens in healthy volunteers, the steady state is reached on day 2 with an average exposure ratio about 15% higher than after a single dose. Steady-state enoxaparin activity levels are well predicted by single-dose pharmacokinetics. After repeated subcutaneous administration of the 1 mg/kg twice daily regimen, the steady state is reached from day 4 with mean exposure about 65% higher than after a single dose and mean peak and trough levels of about 1.2 and 0.52 IU/mL, respectively. Based on enoxaparin sodium pharmacokinetics, this difference in steady state is expected and within the therapeutic range.

    Although not studied clinically, the 150 mg/mL concentration of enoxaparin sodium is projected to result in anticoagulant activities similar to those of 100 mg/mL and 200 mg/mL concentrations at the same enoxaparin dose. When a daily 1.5 mg/kg SC injection of enoxaparin sodium was given to 25 healthy male and female subjects using a 100 mg/mL or a 200 mg/mL concentration the following pharmacokinetic profiles were obtained [see Table 13].

    Table 13 Pharmacokinetic Parametersa After 5 Days of 1.5 mg/kg SC Once Daily Doses of Enoxaparin Sodium Using 100 mg/mL or 200 mg/mL Concentrations
    Concentration Anti-Xa Anti-IIa Heptest aPTT

    Amax
    (IU/mL or Δ sec)

    100 mg/mL

    1.37 (±0.23)

    0.23 (±0.05)

    105 (±17)

    19 (±5)

    200 mg/mL

    1.45 (±0.22)

    0.26 (±0.05)

    111 (±17)

    22 (±7)

    90% CI

    102–110%

    102–111%

    tmax b (h)

    100 mg/mL

    3 (2–6)

    4 (2–5)

    2.5 (2–4.5)

    3 (2–4.5)

    200 mg/mL

    3.5 (2–6)

    4.5 (2.5–6)

    3.3 (2–5)

    3 (2–5)

    AUC (ss)
    (haIU/mL or ha Δ sec)

    100 mg/mL

    14.26 (±2.93)

    1.54 (±0.61)

    1321 (±219)

    200 mg/mL

    15.43 (±2.96)

    1.77 (±0.67)

    1401 (±227)

    90% CI

    105–112%

    103–109%

    a) Means ± SD at Day 5 and 90% Confidence Interval (CI) of the ratio

    b) Median (range)

    Distribution: The volume of distribution of anti-Factor Xa activity is about 4.3 L.

    Elimination: Following intravenous (IV) dosing, the total body clearance of enoxaparin is 26 mL/min. After IV dosing of enoxaparin labeled with the gamma-emitter, 99mTc, 40% of radioactivity and 8 to 20% of anti-Factor Xa activity were recovered in urine in 24 hours. Elimination half-life based on anti-Factor Xa activity was 4.5 hours after a single SC dose to about 7 hours after repeated dosing. Significant anti-Factor Xa activity persists in plasma for about 12 hours following a 40 mg SC once a day dose.

    Following SC dosing, the apparent clearance (CL/F) of enoxaparin is approximately 15 mL/min.

    Metabolism: Enoxaparin sodium is primarily metabolized in the liver by desulfation and/or depolymerization to lower molecular weight species with much reduced biological potency. Renal clearance of active fragments represents about 10% of the administered dose and total renal excretion of active and non-active fragments 40% of the dose.

    Special Populations

    Gender: Apparent clearance and Amax derived from anti-Factor Xa values following single SC dosing (40 mg and 60 mg) were slightly higher in males than in females. The source of the gender difference in these parameters has not been conclusively identified; however, body weight may be a contributing factor.

    Geriatric: Apparent clearance and Amax derived from anti-Factor Xa values following single and multiple SC dosing in geriatric subjects were close to those observed in young subjects. Following once a day SC dosing of 40 mg enoxaparin, the Day 10 mean area under anti-Factor Xa activity versus time curve (AUC) was approximately 15% greater than the mean Day 1 AUC value [see Dosage and Administration (2.3) and Use in Specific Populations (8.5)].

    Renal Impairment: A linear relationship between anti-Factor Xa plasma clearance and creatinine clearance at steady state has been observed, which indicates decreased clearance of enoxaparin sodium in patients with reduced renal function. Anti-Factor Xa exposure represented by AUC, at steady state, is marginally increased in mild (creatinine clearance 50–80 mL/min) and moderate (creatinine clearance 30–50 mL/min) renal impairment after repeated subcutaneous 40 mg once-daily doses. In patients with severe renal impairment (creatinine clearance <30 mL/min), the AUC at steady state is significantly increased on average by 65% after repeated subcutaneous 40 mg once-daily doses [see Dosage and Administration (2.2) and Use in Specific Populations (8.7)].

    Hemodialysis: In a single study, elimination rate appeared similar but AUC was two-fold higher than control population, after a single 0.25 or 0.5 mg/kg intravenous dose.

    Hepatic Impairment: Studies with enoxaparin in patients with hepatic impairment have not been conducted and the impact of hepatic impairment on the exposure to enoxaparin is unknown [see Use in Specific Populations (8.8)].

    Weight: After repeated subcutaneous 1.5 mg/kg once daily dosing, mean AUC of anti-Factor Xa activity is marginally higher at steady state in obese healthy volunteers (BMI 30–48 kg/m2) compared to non-obese control subjects, while Amax is not increased.

    When non-weight adjusted dosing was administered, it was found after a single-subcutaneous 40 mg dose, that anti-Factor Xa exposure is 52% higher in low-weight women (<45 kg) and 27% higher in low-weight men (<57 kg) when compared to normal weight control subjects [see Use in Specific Populations (8.9)].

    Pharmacokinetic interaction: No pharmacokinetic interaction was observed between enoxaparin and thrombolytics when administered concomitantly.

    Close
  • 13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

    No long-term studies in animals have been performed to evaluate the carcinogenic potential of enoxaparin. Enoxaparin was not mutagenic in in vitro tests, including the Ames test, mouse lymphoma cell forward mutation test, and human lymphocyte chromosomal aberration test, and the in vivo rat bone marrow chromosomal aberration test. Enoxaparin was found to have no effect on fertility or reproductive performance of male and female rats at SC doses up to 20 mg/kg/day or 141 mg/m2/day. The maximum human dose in clinical trials was 2.0 mg/kg/day or 78 mg/m2/day (for an average body weight of 70 kg, height of 170 cm, and body surface area of 1.8 m2).

    13.2 Animal Toxicology and/or Pharmacology

    A single SC dose of 46.4 mg/kg enoxaparin was lethal to rats. The symptoms of acute toxicity were ataxia, decreased motility, dyspnea, cyanosis, and coma.

    13.3 Reproductive and Developmental Toxicology

    Teratology studies have been conducted in pregnant rats and rabbits at SC doses of enoxaparin up to 30 mg/kg/day corresponding to 211 mg/m2/day and 410 mg/m2/day in rats and rabbits respectively. There was no evidence of teratogenic effects or fetotoxicity due to enoxaparin.

    Close
  • 14 CLINICAL STUDIES

    14.1 Prophylaxis of Deep Vein Thrombosis Following Abdominal Surgery in Patients at Risk for Thromboembolic Complications

    Abdominal surgery patients at risk include those who are over 40 years of age, obese, undergoing surgery under general anesthesia lasting longer than 30 minutes or who have additional risk factors such as malignancy or a history of deep vein thrombosis (DVT) or pulmonary embolism (PE).

    In a double-blind, parallel group study of patients undergoing elective cancer surgery of the gastrointestinal, urological, or gynecological tract, a total of 1116 patients were enrolled in the study, and 1115 patients were treated. Patients ranged in age from 32 to 97 years (mean age 67 years) with 52.7% men and 47.3% women. Patients were 98% Caucasian, 1.1% Black, 0.4% Asian and 0.4% others. Lovenox 40 mg SC, administered once a day, beginning 2 hours prior to surgery and continuing for a maximum of 12 days after surgery, was comparable to heparin 5000 U every 8 hours SC in reducing the risk of DVT. The efficacy data are provided below [see Table 14].

    Table 14 Efficacy of Lovenox in the Prophylaxis of Deep Vein Thrombosis Following Abdominal Surgery
    Indication Dosing Regimen
    Lovenox
    40 mg q.d. SC
    n (%)
    Heparin
    5000 U q8h SC
    n (%)

    All Treated Abdominal Surgery Patients

    555 (100)

    560 (100)

    Treatment Failures

      Total VTEa (%)

    56 (10.1)
    (95% CIb: 8 to 13)

    63 (11.3)
    (95% CI: 9 to 14)

      DVT Only (%)

    54 (9.7)
    (95% CI: 7 to 12)

    61 (10.9)
    (95% CI: 8 to 13)

    a) VTE = Venous thromboembolic events which included DVT, PE, and death considered to be thromboembolic in origin

    b) CI = Confidence Interval

    In a second double-blind, parallel group study, Lovenox 40 mg SC once a day was compared to heparin 5000 U every 8 hours SC in patients undergoing colorectal surgery (one-third with cancer). A total of 1347 patients were randomized in the study and all patients were treated. Patients ranged in age from 18 to 92 years (mean age 50.1 years) with 54.2% men and 45.8% women. Treatment was initiated approximately 2 hours prior to surgery and continued for approximately 7 to 10 days after surgery. The efficacy data are provided below [see Table 15].

    Table 15 Efficacy of Lovenox in the Prophylaxis of Deep Vein Thrombosis Following Colorectal Surgery
    Indication Dosing Regimen
    Lovenox
    40 mg q.d. SC
    n (%)
    Heparin
    5000 U q8h SC
    n (%)

    All Treated Colorectal Surgery Patients

    673 (100)

    674 (100)

    Treatment Failures

      Total VTEa (%)

    48 (7.1)
    (95% CIb: 5 to 9)

    45 (6.7)
    (95% CI: 5 to 9)

      DVT Only (%)

    47 (7.0)
    (95% CI: 5 to 9)

    44 (6.5)
    (95% CI: 5 to 8)

    a) VTE = Venous thromboembolic events which included DVT, PE, and death considered to be thromboembolic in origin

    b) CI = Confidence Interval

    14.2 Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery

    Lovenox has been shown to reduce the risk of post-operative deep vein thrombosis (DVT) following hip or knee replacement surgery.

    In a double-blind study, Lovenox 30 mg every 12 hours SC was compared to placebo in patients with hip replacement. A total of 100 patients were randomized in the study and all patients were treated. Patients ranged in age from 41 to 84 years (mean age 67.1 years) with 45% men and 55% women. After hemostasis was established, treatment was initiated 12 to 24 hours after surgery and was continued for 10 to 14 days after surgery. The efficacy data are provided below [see Table 16].

    Table 16 Efficacy of Lovenox in the Prophylaxis of Deep Vein Thrombosis Following Hip Replacement Surgery
    Indication Dosing Regimen
    Lovenox
    30 mg q12h SC
    n (%)
    Placebo
    q12h SC
    n (%)

    All Treated Hip Replacement Patients

    50 (100)

    50 (100)

    Treatment Failures

      Total DVT (%)

    5 (10)a

    23 (46)

      Proximal DVT (%)

    1 (2)b

    11 (22)

    a) p value versus placebo = 0.0002

    b) p value versus placebo = 0.0134

    A double-blind, multicenter study compared three dosing regimens of Lovenox in patients with hip replacement. A total of 572 patients were randomized in the study and 568 patients were treated. Patients ranged in age from 31 to 88 years (mean age 64.7 years) with 63% men and 37% women. Patients were 93% Caucasian, 6% Black, <1% Asian, and 1% others. Treatment was initiated within two days after surgery and was continued for 7 to 11 days after surgery. The efficacy data are provided below [see Table 17].

    Table 17 Efficacy of Lovenox in the Prophylaxis of Deep Vein Thrombosis Following Hip Replacement Surgery
    Indication Dosing Regimen
    10 mg q.d. SC
    n (%)
    30 mg q12h SC
    n (%)
    40 mg q.d. SC
    n (%)

    All Treated Hip Replacement Patients

    161 (100)

    208 (100)

    199 (100)

    Treatment Failures

      Total DVT (%)

    40 (25)

    22 (11)a

    27 (14)

      Proximal DVT (%)

    17 (11)

    8 (4)b

    9 (5)

    a) p value versus Lovenox 10 mg once a day = 0.0008

    b) p value versus Lovenox 10 mg once a day = 0.0168

    There was no significant difference between the 30 mg every 12 hours and 40 mg once a day regimens. In a double-blind study, Lovenox 30 mg every 12 hours SC was compared to placebo in patients undergoing knee replacement surgery. A total of 132 patients were randomized in the study and 131 patients were treated, of which 99 had total knee replacement and 32 had either unicompartmental knee replacement or tibial osteotomy. The 99 patients with total knee replacement ranged in age from 42 to 85 years (mean age 70.2 years) with 36.4% men and 63.6% women. After hemostasis was established, treatment was initiated 12 to 24 hours after surgery and was continued up to 15 days after surgery. The incidence of proximal and total DVT after surgery was significantly lower for Lovenox compared to placebo. The efficacy data are provided below [see Table 18].

    Table 18 Efficacy of Lovenox in the Prophylaxis of Deep Vein Thrombosis Following Total Knee Replacement Surgery
    Indication Dosing Regimen
    Lovenox
    30 mg q12h SC
    n (%)
    Placebo
    q12h SC
    n (%)

    All Treated Total Knee Replacement Patients

    47 (100)

    52 (100)

    Treatment Failures

      Total DVT (%)

    5 (11)a
    (95% CIb: 1 to 21)

    32 (62)
    (95% CI: 47 to 76)

      Proximal DVT (%)

    0 (0)c
    (95% Upper CLd: 5)

    7 (13)
    (95% CI: 3 to 24)

    a) p value versus placebo = 0.0001

    b) CI = Confidence Interval

    c) p value versus placebo = 0.013

    d) CL = Confidence Limit

    In a second study, patients undergoing hip replacement surgery were treated, while hospitalized, with Lovenox 40 mg SC, initiated up to 12 hours prior to surgery. All patients were examined for clinical signs and symptoms of venous thromboembolic (VTE) disease. In a double-blind design, patients without clinical signs and symptoms of VTE disease were randomized to a post-discharge regimen of either Lovenox 40 mg (n = 131) once a day SC or to placebo (n = 131) for 3 weeks. A total of 262 patients were randomized in the study double-blind phase and all patients were treated. Patients ranged in age from 44 to 87 years (mean age 68.5 years) with 43.1% men and 56.9% women. Similar to the first study the incidence of DVT during extended prophylaxis was significantly lower for Lovenox compared to placebo, with a statistically significant difference in both total DVT (Lovenox 21 [16%] versus placebo 45 [34%]; p = 0.001) and proximal DVT (Lovenox 8 [6%] versus placebo 28 [21%]; p = <0.001).

    14.3 Prophylaxis of Deep Vein Thrombosis in Medical Patients with Severely Restricted Mobility During Acute Illness

    In a double blind multicenter, parallel group study, Lovenox 20 mg or 40 mg once a day SC was compared to placebo in the prophylaxis of deep vein thrombosis (DVT) in medical patients with severely restricted mobility during acute illness (defined as walking distance of <10 meters for ≤3 days). This study included patients with heart failure (NYHA Class III or IV); acute respiratory failure or complicated chronic respiratory insufficiency (not requiring ventilatory support): acute infection (excluding septic shock); or acute rheumatic disorder [acute lumbar or sciatic pain, vertebral compression (due to osteoporosis or tumor), acute arthritic episodes of the lower extremities]. A total of 1102 patients were enrolled in the study, and 1073 patients were treated. Patients ranged in age from 40 to 97 years (mean age 73 years) with equal proportions of men and women. Treatment continued for a maximum of 14 days (median duration 7 days). When given at a dose of 40 mg once a day SC, Lovenox significantly reduced the incidence of DVT as compared to placebo. The efficacy data are provided below [see Table 20].

    Table 20 Efficacy of Lovenox in the Prophylaxis of Deep Vein Thrombosis in Medical Patients with Severely Restricted Mobility During Acute Illness
    Indication Dosing Regimen
    Lovenox
    20 mg q.d. SC
    n (%)
    Lovenox
    40 mg q.d. SC
    n (%)
    Placebo

    n (%)

    All Treated Medical Patients During Acute Illness

    351 (100)

    360 (100)

    362 (100)

    Treatment Failurea

    Total VTEb (%)

    43 (12.3)

    16 (4.4)

    43 (11.9)

    Total DVT (%)

    43 (12.3)
    (95% CIc 8.8 to 15.7)

    16 (4.4)
    (95% CIc 2.3 to 6.6)

    41 (11.3)
    (95% CIc 8.1 to 14.6)

    Proximal DVT (%)

    13 (3.7)

    5 (1.4)

    14 (3.9)

    a) Treatment failures during therapy, between Days 1 and 14

    b) At approximately 3 months following enrollment, the incidence of venous thromboembolism remained significantly lower in the Lovenox 40 mg treatment group versus the placebo treatment group

    c) CI = Confidence Interval

    14.4 Treatment of Deep Vein Thrombosis with or without Pulmonary Embolism

    In a multicenter, parallel group study, 900 patients with acute lower extremity deep vein thrombosis (DVT) with or without pulmonary embolism (PE) were randomized to an inpatient (hospital) treatment of either (i) Lovenox 1.5 mg/kg once a day SC, (ii) Lovenox 1 mg/kg every 12 hours SC, or (iii) heparin IV bolus (5000 IU) followed by a continuous infusion (administered to achieve an aPTT of 55 to 85 seconds). A total of 900 patients were randomized in the study and all patients were treated. Patients ranged in age from 18 to 92 years (mean age 60.7 years) with 54.7% men and 45.3% women. All patients also received warfarin sodium (dose adjusted according to PT to achieve an International Normalization Ratio [INR] of 2.0 to 3.0), commencing within 72 hours of initiation of Lovenox or standard heparin therapy, and continuing for 90 days. Lovenox or standard heparin therapy was administered for a minimum of 5 days and until the targeted warfarin sodium INR was achieved. Both Lovenox regimens were equivalent to standard heparin therapy in reducing the risk of recurrent venous thromboembolism (DVT and/or PE). The efficacy data are provided below [see Table 21].

    Table 21 Efficacy of Lovenox in Treatment of Deep Vein Thrombosis with or without Pulmonary Embolism
    Indication Dosing Regimena
    Lovenox
    1.5 mg/kg q.d. SC

    n (%)
    Lovenox
    1 mg/kg q12h SC

    n (%)
    Heparin
    aPTT Adjusted IV Therapy
    n (%)

    All Treated DVT Patients with or without PE

    298 (100)

    312 (100)

    290 (100)

    Patient Outcome

    Total VTEb (%)

    13 (4.4)c

    9 (2.9) c

    12 (4.1)

    DVT Only (%)

    11 (3.7)

    7 (2.2)

    8 (2.8)

    Proximal DVT (%)

    9 (3.0)

    6 (1.9)

    7 (2.4)

    PE (%)

    2 (0.7)

    2 (0.6)

    4 (1.4)

    a) All patients were also treated with warfarin sodium commencing within 72 hours of Lovenox or standard heparin therapy.

    b) VTE = venous thromboembolic event (DVT and/or PE)

    c)The 95% Confidence Intervals for the treatment differences for total VTE were:
    Lovenox once a day versus heparin (-3.0 to 3.5)
    Lovenox every 12 hours versus heparin (-4.2 to 1.7)

    Similarly, in a multicenter, open-label, parallel group study, patients with acute proximal DVT were randomized to Lovenox or heparin. Patients who could not receive outpatient therapy were excluded from entering the study. Outpatient exclusion criteria included the following: inability to receive outpatient heparin therapy because of associated co-morbid conditions or potential for non-compliance and inability to attend follow-up visits as an outpatient because of geographic inaccessibility. Eligible patients could be treated in the hospital, but ONLY Lovenox patients were permitted to go home on therapy (72%). A total of 501 patients were randomized in the study and all patients were treated. Patients ranged in age from 19 to 96 years (mean age 57.8 years) with 60.5% men and 39.5% women. Patients were randomized to either Lovenox 1 mg/kg every 12 hours SC or heparin IV bolus (5000 IU) followed by a continuous infusion administered to achieve an aPTT of 60 to 85 seconds (in-patient treatment). All patients also received warfarin sodium as described in the previous study. Lovenox or standard heparin therapy was administered for a minimum of 5 days. Lovenox was equivalent to standard heparin therapy in reducing the risk of recurrent venous thromboembolism. The efficacy data are provided below [see Table 22].

    Table 22 Efficacy of Lovenox in Treatment of Deep Vein Thrombosis
    Indication Dosing Regimena
    Lovenox
    1 mg/kg q12h SC
    Heparin
    aPTT Adjusted IV Therapy
    n (%) n (%)

    All Treated DVT Patients

    247 (100)

    254 (100)

    Patient Outcome

    Total VTEb (%)

    13 (5.3)c

    17 (6.7)

    DVT Only (%)

    11 (4.5)

    14 (5.5)

    Proximal DVT (%)

    10 (4.0)

    12 (4.7)

    PE (%)

    2 (0.8)

    3 (1.2)

    a) All patients were also treated with warfarin sodium commencing on the evening of the second day of Lovenox or standard heparin therapy.

    b) VTE = venous thromboembolic event (deep vein thrombosis [DVT] and/or pulmonary embolism [PE]).

    c) The 95% Confidence Intervals for the treatment difference for total VTE was: Lovenox versus heparin (- 5.6 to 2.7).

    14.5 Prophylaxis of Ischemic Complications in Unstable Angina and Non-Q-Wave Myocardial Infarction

    In a multicenter, double-blind, parallel group study, patients who recently experienced unstable angina or non-Q-wave myocardial infarction were randomized to either Lovenox 1 mg/kg every 12 hours SC or heparin IV bolus (5000 U) followed by a continuous infusion (adjusted to achieve an aPTT of 55 to 85 seconds). A total of 3171 patients were enrolled in the study, and 3107 patients were treated. Patients ranged in age from 25–94 years (median age 64 years), with 33.4% of patients female and 66.6% male. Race was distributed as follows: 89.8% Caucasian, 4.8% Black, 2.0% Asian, and 3.5% other. All patients were also treated with aspirin 100 to 325 mg per day. Treatment was initiated within 24 hours of the event and continued until clinical stabilization, revascularization procedures, or hospital discharge, with a maximal duration of 8 days of therapy. The combined incidence of the triple endpoint of death, myocardial infarction, or recurrent angina was lower for Lovenox compared with heparin therapy at 14 days after initiation of treatment. The lower incidence of the triple endpoint was sustained up to 30 days after initiation of treatment. These results were observed in an analysis of both all-randomized and all-treated patients. The efficacy data are provided below [see Table 23].

    Table 23 Efficacy of Lovenox in the Prophylaxis of Ischemic Complications in Unstable Angina and Non-Q-Wave Myocardial Infarction (Combined Endpoint of Death, Myocardial Infarction, or Recurrent Angina)
    Indication Dosing Regimena
    Reduction
    (%)

    p Value
    Lovenox
    1mg/kg q12h SC
    Heparin
    aPTT Adjusted IV Therapy
    n (%) n (%)

    All Treated Unstable Angina and Non-Q-Wave MI Patients

    1578 (100)

    1529 (100)

    Timepointb

      48 Hours

    96 (6.1)

    112 (7.3)

    1.2

    0.120

      14 Days

    261 (16.5)

    303 (19.8)

    3.3

    0.017

      30 Days

    313 (19.8)

    358 (23.4)

    3.6

    0.014

    a) All patients were also treated with aspirin 100 to 325 mg per day.

    b) Evaluation timepoints are after initiation of treatment. Therapy continued for up to 8 days (median duration of 2.6 days).

    The combined incidence of death or myocardial infarction at all time points was lower for Lovenox compared to standard heparin therapy, but did not achieve statistical significance. The efficacy data are provided below [see Table 24].

    Table 24 Efficacy of Lovenox in the Prophylaxis of Ischemic Complications in Unstable Angina and Non-Q-Wave Myocardial Infarction (Combined Endpoint of Death or Myocardial Infarction)
    Indication Dosing Regimena
    Reduction
    (%)

    p Value
    Lovenox
    1 mg/kg q12h SC
    n (%)
    Heparin
    aPTT Adjusted IV Therapy
    n (%)

    All Treated Unstable Angina and Non-Q-Wave MI Patients

    1578 (100)

    1529 (100)

    Timepointb

      48 Hours

    16 (1.0)

    20 (1.3)

    0.3

    0.126

      14 Days

    76 (4.8)

    93 (6.1)

    1.3

    0.115

      30 Days

    96 (6.1)

    118 (7.7)

    1.6

    0.069

    a) All patients were also treated with aspirin 100 to 325 mg per day.

    b) Evaluation timepoints are after initiation of treatment. Therapy continued for up to 8 days (median duration of 2.6 days).

    In a survey one year following treatment, with information available for 92% of enrolled patients, the combined incidence of death, myocardial infarction, or recurrent angina remained lower for Lovenox versus heparin (32.0% vs 35.7%).

    Urgent revascularization procedures were performed less frequently in the Lovenox group as compared to the heparin group, 6.3% compared to 8.2% at 30 days (p = 0.047).

    14.6 Treatment of Acute ST-Segment Elevation Myocardial Infarction

    In a multicenter, double-blind, double-dummy, parallel group study, patients with acute ST-segment elevation myocardial infarction (STEMI) who were to be hospitalized within 6 hours of onset and were eligible to receive fibrinolytic therapy were randomized in a 1:1 ratio to receive either Lovenox or unfractionated heparin.

    Study medication was initiated between 15 minutes before and 30 minutes after the initiation of fibrinolytic therapy. Unfractionated heparin was administered beginning with an IV bolus of 60 U/kg (maximum 4000 U) and followed with an infusion of 12 U/kg per hour (initial maximum 1000 U per hour) that was adjusted to maintain an aPTT of 1.5 to 2 times the control value. The IV infusion was to be given for at least 48 hours. The enoxaparin dosing strategy was adjusted according to the patient's age and renal function. For patients younger than 75 years of age, enoxaparin was given as a single 30 mg intravenous bolus plus a 1 mg/kg SC dose followed by an SC injection of 1 mg/kg every 12 hours. For patients at least 75 years of age, the IV bolus was not given and the SC dose was reduced to 0.75 mg/kg every 12 hours. For patients with severe renal insufficiency (estimated creatinine clearance of less than 30 mL per minute), the dose was to be modified to 1 mg/kg every 24 hours. The SC injections of enoxaparin were given until hospital discharge or for a maximum of eight days (whichever came first). The mean treatment duration for enoxaparin was 6.6 days. The mean treatment duration of unfractionated heparin was 54 hours.

    When percutaneous coronary intervention was performed during study medication period, patients received antithrombotic support with blinded study drug. For patients on enoxaparin, the PCI was to be performed on enoxaparin (no switch) using the regimen established in previous studies, i.e. no additional dosing, if the last SC administration was less than 8 hours before balloon inflation, IV bolus of 0.3 mg/kg enoxaparin if the last SC administration was more than 8 hours before balloon inflation.

    All patients were treated with aspirin for a minimum of 30 days. Eighty percent of patients received a fibrin-specific agent (19% tenecteplase, 5% reteplase and 55% alteplase) and 20% received streptokinase.

    Among 20,479 patients in the ITT population, the mean age was 60 years, and 76% were male. Racial distribution was: 87% Caucasian, 9.8% Asian, 0.2% Black, and 2.8% other. Medical history included previous MI (13%), hypertension (44%), diabetes (15%) and angiographic evidence of CAD (5%). Concomitant medication included aspirin (95%), beta-blockers (86%), ACE inhibitors (78%), statins (70%) and clopidogrel (27%). The MI at entry was anterior in 43%, non-anterior in 56%, and both in 1%.

    The primary efficacy end point was the composite of death from any cause or myocardial re-infarction in the first 30 days after randomization. Total follow-up was one year.

    The rate of the primary efficacy end point (death or myocardial re-infarction) was 9.9% in the enoxaparin group, and 12.0% in the unfractionated heparin group, a 17% reduction in the relative risk, (P=0.000003) [see Table 25].

    Table 25 Efficacy of Lovenox in the Treatment of Acute ST-Segment Elevation Myocardial Infarction
    Enoxaparin
    (N=10,256)
    UFH
    (N=10,223)
    Relative Risk
    (95% CI)
    P Value

    Outcome at 48 hours

    n (%)

    n (%)

    Death or Myocardial Re-infarction

    478 (4.7)

    531 (5.2)

    0.90 (0.80 to 1.01)

    0.08

      Death

    383 (3.7)

    390 (3.8)

    0.98 (0.85 to 1.12)

    0.76

      Myocardial Re-infarction

    102 (1.0)

    156 (1.5)

    0.65 (0.51 to 0.84)

    <0.001

    Urgent Revascularization

    74 (0.7)

    96 (0.9)

    0.77 (0.57 to 1.04)

    0.09

    Death or Myocardial Re-infarction or Urgent Revascularization

    548 (5.3)

    622 (6.1)

    0.88 (0.79 to 0.98)

    0.02

    Outcome at 8 Days

    Death or Myocardial Re-infarction

    740 (7.2)

    954 (9.3)

    0.77 (0.71 to 0.85)

    <0.001

      Death

    559 (5.5)

    605 (5.9)

    0.92 (0.82 to 1.03)

    0.15

      Myocardial Re-infarction

    204 (2.0)

    379 (3.7)

    0.54 (0.45 to 0.63)

    <0.001

    Urgent Revascularization

    145 (1.4)

    247 (2.4)

    0.59 (0.48 to 0.72)

    <0.001

    Death or Myocardial Re-infarction or Urgent Revascularization

    874 (8.5)

    1181 (11.6)

    0.74 (0.68 to 0.80)

    <0.001

    Outcome at 30 Days

    Primary efficacy endpoint

    (Death or Myocardial Re-infarction)

    1017 (9.9)

    1223 (12.0)

    0.83 (0.77 to 0.90)

    0.000003

      Death

    708 (6.9)

    765 (7.5)

    0.92 (0.84 to 1.02)

    0.11

      Myocardial Re-infarction

    352 (3.4)

    508 (5.0)

    0.69 (0.60 to 0.79)

    <0.001

    Urgent Revascularization

    213 (2.1)

    286 (2.8)

    0.74 (0.62 to 0.88)

    <0.001

    Death or Myocardial Re-infarction or Urgent Revascularization

    1199 (11.7)

    1479 (14.5)

    0.81 (0.75 to 0.87)

    <0.001

    Note: Urgent revascularization denotes episodes of recurrent myocardial ischemia (without infarction) leading to the clinical decision to perform coronary revascularization during the same hospitalization. CI denotes confidence intervals.

    The beneficial effect of enoxaparin on the primary end point was consistent across key subgroups including age, gender, infarct location, history of diabetes, history of prior myocardial infarction, fibrinolytic agent administered, and time to treatment with study drug (see Figure 1); however, it is necessary to interpret such subgroup analyses with caution.

    Figure 1. Relative Risks of and Absolute Event Rates for the Primary End Point at 30 Days in Various Subgroupsa

    Figure 1

    a) The primary efficacy end point was the composite of death from any cause or myocardial re-infarction in the first 30 days. The overall treatment effect of enoxaparin as compared to the unfractionated heparin is shown at the bottom of the figure. For each subgroup, the circle is proportional to the number and represents the point estimate of the treatment effect and the horizontal lines represent the 95 percent confidence intervals. Fibrin-specific fibrinolytic agents included alteplase, tenecteplase and reteplase. Time to treatment indicates the time from the onset of symptoms to the administration of study drug (median, 3.2 hours).

    The beneficial effect of enoxaparin on the primary end point observed during the first 30 days was maintained over a 12 month follow-up period (see Figure 2).

    Figure 2 - Kaplan-Meier plot - death or myocardial re-infarction at 30 days - ITT population

    Figure 2

    There is a trend in favor of enoxaparin during the first 48 hours, but most of the treatment difference is attributed to a step increase in the event rate in the UFH group at 48 hours (seen in Figure 2 ), an effect that is more striking when comparing the event rates just prior to and just subsequent to actual times of discontinuation. These results provide evidence that UFH was effective and that it would be better if used longer than 48 hours. There is a similar increase in endpoint event rate when enoxaparin was discontinued, suggesting that it too was discontinued too soon in this study.

    The rates of major hemorrhages (defined as requiring 5 or more units of blood for transfusion, or 15% drop in hematocrit or clinically overt bleeding, including intracranial hemorrhage) at 30 days were 2.1% in the enoxaparin group and 1.4% in the unfractionated heparin group. The rates of intracranial hemorrhage at 30 days were 0.8% in the enoxaparin group 0.7% in the unfractionated heparin group. The 30-day rate of the composite endpoint of death, myocardial re-infarction or ICH (a measure of net clinical benefit) was significantly lower in the enoxaparin group (10.1%) as compared to the heparin group (12.2%).

    Close
  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    Lovenox is available in two concentrations [see Tables 26 and 27]:

    Table 26 100 mg/mL Concentration
    Dosage Unit / Strengtha Anti-Xa Activityb Package Size
    (per carton)
    Label Color NDC # 0075-

    Prefilled Syringesc

    30 mg/0.3 mL

    3000 IU

    10 syringes

    Medium Blue

    0624-30

    40 mg/0.4 mL

    4000 IU

    10 syringes

    Yellow

    0620-40

    Graduated Prefilled Syringesc

    60 mg/0.6 mL

    6000 IU

    10 syringes

    Orange

    0621-60

    80 mg/0.8 mL

    8000 IU

    10 syringes

    Brown

    0622-80

    100 mg/1 mL

    10,000 IU

    10 syringes

    Black

    0623-00

    Multiple-Dose Viald

    300 mg/ 3 mL

    30,000 IU

    1 vial

    Red

    0626-03

    a) Strength represents the number of milligrams of enoxaparin sodium in Water for Injection. Lovenox 30 and 40 mg prefilled syringes, and 60, 80, and 100 mg graduated prefilled syringes each contain 10 mg enoxaparin sodium per 0.1 mL Water for Injection

    b) Approximate anti-Factor Xa activity based on reference to the W.H.O. First International Low Molecular Weight Heparin Reference Standard.

    c) Each Lovenox prefilled syringe is for single, one-time use only and is affixed with a 27 gauge × 1/2 inch needle.

    d) Each Lovenox multiple-dose vial contains 15 mg benzyl alcohol per 1 mL as a preservative.

    Table 27 150 mg/mL Concentration
    Dosage Unit / Strengtha Anti-Xa Activityb Package Size
    (per carton)
    Syringe Label Color NDC # 0075-

    Graduated Prefilled Syringesc

      120 mg / 0.8 mL

    12,000 IU

    10 syringes

    Purple

    2912-01

      150 mg / 1 mL

    15,000 IU

    10 syringes

    Navy Blue

    2915-01

    a) Strength represents the number of milligrams of enoxaparin sodium in Water for Injection. Lovenox 120 and 150 mg graduated prefilled syringes contain 15 mg enoxaparin sodium per 0.1 mL Water for Injection.

    b) Approximate anti-Factor Xa activity based on reference to the W.H.O. First International Low Molecular Weight Heparin Reference Standard.

    c) Each Lovenox graduated prefilled syringe is for single, one-time use only and is affixed with a 27 gauge × 1/2 inch needle.

    Store at 25°C (77°F); excursions permitted to 15–30°C (59–86°F) [see USP Controlled Room Temperature].

    Do not store the multiple-dose vials for more than 28 days after the first use.

    Keep out of the reach of children.

    Close
  • 17 PATIENT COUNSELING INFORMATION

    If patients have had neuraxial anesthesia or spinal puncture, and particularly, if they are taking concomitant NSAIDs, platelet inhibitors, or other anticoagulants, they should be informed to watch for signs and symptoms of spinal or epidural hematoma, such as tingling, numbness (especially in the lower limbs) and muscular weakness. If any of these symptoms occur the patient should contact his or her physician immediately.

    Additionally, the use of aspirin and other NSAIDs may enhance the risk of hemorrhage. Their use should be discontinued prior to enoxaparin therapy whenever possible; if co-administration is essential, the patient's clinical and laboratory status should be closely monitored [see Drug Interactions (7)].

    Patients should also be informed:

    1
    of the instructions for injecting Lovenox if their therapy is to continue after discharge from the hospitals.
    2
    it may take them longer than usual to stop bleeding.
    3
    they may bruise and/or bleed more easily when they are treated with Lovenox.
    4
    they should report any unusual bleeding, bruising, or signs of thrombocytopenia (such as a rash of dark red spots under the skin) to their physician [see Warnings and Precautions (5.1, 5.5)].
    5
    to tell their physicians and dentists they are taking Lovenox and/or any other product known to affect bleeding before any surgery is scheduled and before any new drug is taken [see Warnings and Precautions (5.3)].
    6
    to tell their physicians and dentists of all medications they are taking, including those obtained without a prescription, such as aspirin or other NSAIDs [see Drug Interactions (7)].
    Close
  • SPL UNCLASSIFIED SECTION

    sanofi-aventis U.S. LLC
    Bridgewater, NJ 08807
    A SANOFI COMPANY

    Multiple-dose vials are also manufactured by DSM Pharmaceuticals, Inc.
    Greenville, NC 27835

    © 2013 sanofi-aventis U.S. LLC

    06/13

    Close
  • Principal Display Panel - 30 mg Bag

    Lovenox® 30 mg/0.3 ml [100mg/mL]

    Enoxaparin Sodium Injection

    5 x 0.3 ml Syringes

    Bag
    Close
  • Principal Display Panel - 40 mg bag

    Lovenox® 40 mg/0.4 ml [100mg/mL]

    Enoxaparin Sodium Injection

    5 x 0.4 ml Syringes

    Bag Label
    Close
  • Principal Display Panel - 60 mg Bag

    Lovenox® 60 mg/0.6 ml [100 mg/mL]

    Enoxaparin Sodium Injection

    5 x 0.6 ml Syringes

    Bag Label
    Close
  • Principal display panel - 80 mg bag

    Lovenox® 80 mg/0.8 ml [100 MG/ML]

    Enoxaparin Sodium Injection

    5 x 0.8 ml Syringes

    Bag Label
    Close
  • principal display panel - 100 mg bag

    Lovenox® 100 mg/1 mL

    Enoxaparin Sodium Injection

    5 x 1 ml Syringes

    Bag Label
    Close
  • INGREDIENTS AND APPEARANCE
    LOVENOX 
    enoxaparin sodium injection
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:55154-4024(NDC:0075-0624)
    Route of Administration SUBCUTANEOUS, INTRAVENOUS DEA Schedule     
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    enoxaparin sodium (enoxaparin) enoxaparin sodium 30 mg  in 0.3 mL
    Inactive Ingredients
    Ingredient Name Strength
    water  
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:55154-4024-5 5 in 1 BAG
    1 0.3 mL in 1 SYRINGE
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    NDA NDA020164 03/29/1993
    LOVENOX 
    enoxaparin sodium injection
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:55154-4028(NDC:0075-0620)
    Route of Administration SUBCUTANEOUS, INTRAVENOUS DEA Schedule     
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    enoxaparin sodium (enoxaparin) enoxaparin sodium 40 mg  in 0.4 mL
    Inactive Ingredients
    Ingredient Name Strength
    water  
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:55154-4028-5 5 in 1 BAG
    1 0.4 mL in 1 SYRINGE
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    NDA NDA020164 03/29/1993
    LOVENOX 
    enoxaparin sodium injection
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:55154-4029(NDC:0075-0621)
    Route of Administration SUBCUTANEOUS, INTRAVENOUS DEA Schedule     
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    enoxaparin sodium (enoxaparin) enoxaparin sodium 60 mg  in 0.6 mL
    Inactive Ingredients
    Ingredient Name Strength
    water  
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:55154-4029-5 5 in 1 BAG
    1 0.6 mL in 1 SYRINGE
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    NDA NDA020164 03/29/1993
    LOVENOX 
    enoxaparin sodium injection
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:55154-4030(NDC:0075-0622)
    Route of Administration SUBCUTANEOUS, INTRAVENOUS DEA Schedule     
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    enoxaparin sodium (enoxaparin) enoxaparin sodium 80 mg  in 0.8 mL
    Inactive Ingredients
    Ingredient Name Strength
    water  
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:55154-4030-5 5 in 1 BAG
    1 0.8 mL in 1 SYRINGE
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    NDA NDA020164 03/29/1993
    LOVENOX 
    enoxaparin sodium injection
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:55154-4031(NDC:0075-0623)
    Route of Administration SUBCUTANEOUS, INTRAVENOUS DEA Schedule     
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    enoxaparin sodium (enoxaparin) enoxaparin sodium 100 mg  in 1 mL
    Inactive Ingredients
    Ingredient Name Strength
    water  
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:55154-4031-5 5 in 1 BAG
    1 1 mL in 1 SYRINGE
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    NDA NDA020164 03/29/1993
    Labeler - Cardinal Health (188557102)
    Establishment
    Name Address ID/FEI Business Operations
    Cardinal Health 188557102 REPACK(55154-4024, 55154-4028, 55154-4029, 55154-4030, 55154-4031)
    Close